# BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers

> **NCT04824638** · PHASE2 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 267 (actual)

## Conditions studied

- Healthy
- Immunization; Infection

## Interventions

- **BIOLOGICAL:** 3 doses of BNT162b2 vaccine
- **BIOLOGICAL:** 2 dose of BNT162b2 vaccine

## Key facts

- **NCT ID:** NCT04824638
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-08
- **Primary completion:** 2021-06-30
- **Final completion:** 2023-12-02
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04824638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04824638, "BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT04824638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*